Abstract: A quasi-macroscopic cold field emission electron gun and a manufacturing method thereof are provided, which includes a filament device and an electron gun base, wherein the filament device includes a cold cathode filament and a conductive capillary tube, the cold cathode filament passes through one end of the conductive capillary tube and is crimped through a pressing groove device, the other end of the conductive capillary tube is connected to the electron gun base, and the end of the cold cathode filament is the electron emission end. Through the coaxial nesting and pressing deformation of quasi-macroscopic carbon fiber and metal tube and using of the non welding electrical connection method, this technology avoids the problem that it is not easy to form a reliable electrical connection during the welding process due to the poor wettability between carbon fiber and metal.

Abstract: Provided are a pharmaceutical composition containing an anti-IL-4R antibody and the use thereof. The pharmaceutical composition contains an anti-IL-4R antibody or an antigen-binding fragment thereof in a histidine-acetic acid buffer agent, a viscosity modifier, a surfactant, and a stabilizer.

Abstract: A pharmaceutical composition containing an SOST antibody or an antigen-binding fragment thereof in an acetic acid-sodium acetate buffer solution is described. In addition, the pharmaceutical composition can also contain sugar, a nonionic surfactant or other excipients. After being stored for several months, the pharmaceutical composition exhibits good antibody stability.

Abstract: Provided is a method for preparing glycolic acid which comprises oxidizing glycolaldehyde with molecular oxygen in the presence of a solvent and a supported catalyst. Said supported catalyst comprises (i) a noble metal selected from the group consisting of Pt, Pd, Ru and Rh, (ii) Bi and (iii) a support. Advantageously, the supported metallic catalyst is more active than the catalysts used in prior art. Furthermore, the catalyst is more stable at oxygen rich conditions.

Abstract: The present invention relates to a method of synthesizing at least one organic acid comprising oxidizing glycolaldehyde with nitric acid in the presence of a solvent. Advantageously, it is an industrially applicable process, which prepares organic acid, notably glycolic acid and/or glyoxylic acid in a high yield based on bio-based feedstocks.

Abstract: The present disclosure provides a panel of nucleic acid molecule primers specific for HLA-specific alleles and other genetic polymorphisms, which are useful for quantitatively amplifying these markers to detect, diagnose, and monitor individuals who have or are at risk of certain disease conditions, such as autoimmune disease, proliferative disease, infectious disease, allograft rejection, or pregnancy-related pathologies.

Abstract: Provided are methods for prophylaxis and/or therapy for Phelan-McDermid Syndrome (PMS) and autism spectrum disorder (ASD). The methods involve administering a histone methyltransferase (HMT) inhibitor, a histone deacetylase (HDAC) inhibitor, or a combination thereof, such that one or more symptoms of the PMS and/or the AMD are reduced.

Abstract: The present disclosure provides a panel of nucleic acid molecule primers specific for HLA-specific alleles and other genetic polymorphisms, which are useful for quantitatively amplifying these markers to detect, diagnose, and monitor individuals who have or are at risk of certain disease conditions, such as autoimmune disease, proliferative disease, infectious disease, allograft rejection, or pregnancy-related pathologies.

Abstract: The present invention concerns a process for forming a primary or a secondary amine via amination reaction comprising: reacting an alcohol with an amine in the presence of a zeolite comprising a transition metal chosen in the group consisting of Group 8 to 12 elements of the Periodic Table and any combination thereof.

Abstract: Provided are methods for prophylaxis and/or therapy for Phelan-McDermid Syndrome (PMS) and autism spectrum disorder (ASD). The methods involve administering a hi stone methyltransf erase (HMT) inhibitor, a hi stone deacetylase (HDAC) inhibitor, or a combination thereof, such that one or more symptoms of the PMS and/or the AMD are reduced.

Abstract: The present invention provides an anti-CD27 antibody, an antigen-binding fragment thereof, and a medical use thereof. Specifically, the present invention provides a human antibody comprising the CDR region of the anti-CD27 antibody, and a pharmaceutical composition comprising the human anti-CD27 antibody and an antigen-binding fragment thereof, and a use thereof as an anticancer drug. In particular, the invention provides a human anti-CD27 antibody and a use thereof in the preparation of a drug for the treatment of CD27-mediated diseases or disorders.

Abstract: A stable anti-PD-1 antibody pharmaceutical preparation and an application thereof in a medicine. The anti-PD-1 antibody pharmaceutical preparation comprises an anti-PD-1 antibody, a buffer, and can further comprise at least one type of stabilizer, and optionally can further con a surfactant. The anti-PD-1 antibody pharmaceutical preparation of the present invention can effectively suppress antibody aggregation and deamidation, thereby preventing degradation of an antibody product, obtaining a stable injected pharmaceutical preparation.

Abstract: A stable anti-PD-1 antibody pharmaceutical preparation and an application thereof in a medicine. The anti-PD-1 antibody pharmaceutical preparation comprises an anti-PD-1 antibody, a buffer, and can further comprise at least one type of stabilizer, and optionally can further comprise a surfactant. The anti-PD-1 antibody pharmaceutical preparation of the present invention can effectively suppress antibody aggregation and deamidation, thereby preventing degradation of an antibody product, resulting in a stable injectable pharmaceutical preparation.

Abstract: A pharmaceutical composition containing an SOST antibody or an antigen-binding fragment thereof in an acetic acid-sodium acetate buffer solution is described. In addition, the pharmaceutical composition can also contain sugar, a nonionic surfactant or other excipients. After being stored for several months, the pharmaceutical composition exhibits good antibody stability.

Abstract: The present disclosure provides a panel of nucleic acid molecule primers specific for HLA-specific alleles and other genetic polymorphisms, which are useful for quantitatively amplifying these markers to detect, diagnose, and monitor individuals who have or are at risk of certain disease conditions, such as autoimmune disease, proliferative disease, infectious disease, allograft rejection, or pregnancy-related pathologies.

Abstract: The present disclosure provides a panel of nucleic acid molecule primers specific for HLA-specific alleles and other genetic polymorphisms, which are useful for quantitatively amplifying these markers to detect, diagnose, and monitor individuals who have or are at risk of certain disease conditions, such as autoimmune disease, proliferative disease, infectious disease, allograft rejection, or pregnancy-related pathologies.

Abstract: A stable c-Met antibody-drug conjugate (c-Met ADC) formulation and use thereof in medicine are described. In particular, the formulation contains c-Met ADC, a buffer, and can also contains at least one stabilizer, and optionally a surfactant. The c-Met ADC formulation of the application can effectively inhibit the aggregation and isomerization of antibodies, and prevent the degradation of an antibody product therein, being a stable injectable pharmaceutical formulation.

Abstract: The present disclosure provides a panel of nucleic acid molecule primers specific for HLA-specific alleles and other genetic polymorphisms, which are useful for quantitatively amplifying these markers to detect, diagnose, and monitor individuals who have or are at risk of certain disease conditions, such as autoimmune disease, proliferative disease, infectious disease, allograft rejection, or pregnancy-related pathologies.

Abstract: The present invention provides a PD-L1 antibody pharmaceutical composition and use thereof. In particular, the present invention provides a pharmaceutical composition comprising the PD-L1 antibody or an antigen-binding fragment thereof in a succinate buffer. In addition, the pharmaceutical composition may also contain a sugar and a nonionic surfactant.

Abstract: The present invention discloses an electromagnetic detector and a detection method for detection of interface cracks in a piezoelectric-piezomagnetic laminated structure. The electromagnetic detector for detection of interface crack in a piezoelectric-piezomagnetic laminated structure mainly comprises an eddy current magnetic probe assembly, an automatic scanning frame, a base, a carrier, a servomotor, an X-axis mobile frame driving controller, a Y-axis mobile frame driving controller, a power supply, and a main controller.